Navigation Links
Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
Date:1/28/2011

ive territories, and will mutually decide the most effective method to maximize product opportunities in rest of world (ROW) territories after phase II and share ROW revenues. With the establishment of the partnership Endo has exercised its option to license the lead asset in this collaboration discovered at Orion, a novel androgen-receptor antagonist for the treatment of advanced prostate cancer, which will be developed jointly by both companies for approval globally. It will be entering into phase one clinical trials in the near future.

About Orion

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion’s pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

The Group’s net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion’s A and B shares are listed on NASDAQ OMX Helsinki. For more information, please visit www.orion.fi/en.

Orion markets and distributes European-wide Endo’s product Vantas®.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government
3. JHP Pharmaceuticals and Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
4. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
5. Amylin Pharmaceuticals Reports 2010 Financial Results
6. Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team
7. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
8. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
9. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
10. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
11. Amylin Pharmaceuticals to Webcast Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 Sanomedics ... August 2014 report by Global Research & Data Services, ... per year from 2014 through 2018, as demand for ... States is the world,s largest market for ... with advanced thermometers is Sanomedics International Holdings, Inc. ...
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
Breaking Medicine Technology:Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Inc. (OTC Bulletin Board: AEMD ), the ... disease and cancer, announced today that it has accepted ... Health and Human Services BARDA Industry Day on Wednesday, ... Broad Spectrum Antiviral Platform Technology" is scheduled to begin ...
... 14, 2010 /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. ... the "Company"), a developer, manufacturer and distributor of ... today announced that as of fiscal year ending ... and nerve regulation product - Compound Schisandra Tablets ...
Cached Medicine Technology:Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day 2Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day 3Aethlon Medical Announces Presentation at U.S. Department of Health and Human Services BARDA Industry Day 4China Botanic Achieves Three Million RMB Sales of New Product 2China Botanic Achieves Three Million RMB Sales of New Product 3
(Date:10/22/2014)... 22, 2014 The Louis ... is dedicated to distribute health information technology innovation ... worldwide announced the development of six key guiding ... when receiving healthcare. These are an expansion of ... “providing care that is respectful of and responsive ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... 22, 2014 Richard Carlson, Managing Partner ... leader with over 25 years experience. Mr. Carlson ... the areas related to EDI, B2B Commerce, RFID and ... Editorial Advisory Board member for Pharmaceutical Commerce Magazine and ... Fin Group is a management and technology consulting firm ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... New York, N.Y. February 7, 2008 Obesity ... the U.S. over the last two decades. A new ... characteristics of neighborhoods, including the areas income level, the ... the continuing obesity epidemic. , Researchers led by Jennifer ...
... say this way of checking estrogen-receptor status of participants ... News) -- In epidemiological studies of women with breast ... central laboratory testing for determining the estrogen-receptor status of ... reports is common practice in such studies, but it ...
... February 7, 2008 A seemingly random arterial ... in adults with no previous symptoms may not be ... the Netherlands discovered that many people with congenital aneurismal ... by identifying and treating patients at risk. They reported ...
... OAKLAND, Calif., Feb. 7 Nytera Tilmon works,at a ... her seven children,all of whom live with asthma. The ... television show revealing Nytera,s story and others,behind the healthcare ... Time" and it,s the only national labor-produced TV show., ...
... SINGAPORE, Feb. 7 Flextronics (Nasdaq: FLEX ... Power (FMP) business unit,of CEAG AG, a global ... telephones. FMP develops, produces and markets power supply ... sector.,FMP will become part of Flextronics,components business unit ...
... act as tumor suppressor, keeping bad cells in check ... called STAT3 acts like "Jekyll and Hyde" in glioblastoma brain ... researchers. , The finding may help improve treatment of people ... people in the prime of life and is almost always ...
Cached Medicine News:Health News:Lower-income neighborhoods associated with higher obesity rates 2Health News:Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 2Health News:Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 3
... to its design, this is the ... stone therapy in urinary and biliary ... a multipurpose lithotripter with other applications ... nephrolithotomy. ,The basic system comprises the ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... The Compact Sigma is designed to ... Quick, precise mechanical coupling eliminates clumsy ... be performed as well. Dorniers patented ... too. ,Positioning is simple using the ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: